alecensa alectinib hydrochloride 150 mg hard capsule blister pack
roche products pty ltd - alectinib hydrochloride, quantity: 161.33 mg (equivalent: alectinib, qty 150 mg) - capsule, hard - excipient ingredients: magnesium stearate; potassium chloride; carmellose calcium; maize starch; carnauba wax; hypromellose; hyprolose; titanium dioxide; lactose monohydrate; sodium lauryl sulfate; carrageenan; iron oxide red; iron oxide yellow; indigo carmine aluminium lake; shellac; glyceryl monooleate - alecensa is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive, locally advanced or metastatic non-small cell lung cancer (nsclc).
southphos aluminium phosphide tablets
envirofume limited - aluminium phosphide - aluminium phosphide 570 g/kg - insecticide
alecensa- alectinib hydrochloride capsule
genentech, inc. - alectinib hydrochloride (unii: p9yy73lo6j) (alectinib - unii:lij4ct1z3y) - alectinib 150 mg - alecensa is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc) as detected by an fda-approved test. none. risk summary based on animal studies and its mechanism of action, alecensa can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data on alecensa use in pregnant women. administration of alectinib to pregnant rats and rabbits by oral gavage during the period of organogenesis resulted in embryo-fetal toxicity and abortion at maternally toxic doses with exposures approximately 2.7 times those observed in humans treated with alectinib at 600 mg twice daily (see data) . advise pregnant women of the potential risk to a fetus. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data animal data in a preliminary rabbit embryo-fetal study, adm
alecensa (alectinib) hard capsules 150mg
roche (malaysia) sdn. bhd. - alectinib hydrochloride -
anhydrol forte
trupharm marketing 1985 ltd. - aluminium chloride hexahydrate - solution - aluminium chloride hexahydrate 20 %w/v - aluminium chlorohydrate - aluminium chlorohydrate - for the topical treatment of hyperhydrosis specifically involving axillae, hands or feet.
alecensa
roche pharmaceuticals (israel) ltd - alectinib as hydrochloride - capsules - alectinib as hydrochloride 150 mg - alectinib is indicated for the treatment of patients with alk positive, locally advanced or metastatic non-small cell lung cancer (nsclc) who progressed on or are intolerant to crizotinibalecensa as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc).
aluminium phosphide
national fumigants pty ltd - aluminium phosphide - unknown - aluminium phosphide mineral-aluminium active 0.0 - active constituent
aluminium phosphide
adama australia pty limited - aluminium phosphide - unknown - aluminium phosphide mineral-aluminium active 0.0 - active constituent
aluminium phosphide
redox limited - aluminium phosphide - unknown - aluminium phosphide mineral-aluminium active 0.0 - active constituent
aluminium phosphide
imtrade australia pty ltd - aluminium phosphide - unknown - aluminium phosphide mineral-aluminium active 0.0 - active constituent